Screener
Relmada Therapeutics, Inc. RLMD Q2 2026 earnings
Reported August 6, 2026 · After market close
EPS-$0.11Beat by $0.09
EPS estimate-$0.20
Next report
Nov 12, 2026 (in 2 months)EPS estimate-$0.14
Versus estimates
Diluted EPS
FAQ
- When did Relmada Therapeutics, Inc. report Q2 2026 earnings?
- Relmada Therapeutics, Inc. (RLMD) reported Q2 2026 earnings on August 6, 2026 after market close.
- What were Relmada Therapeutics, Inc.'s Q2 2026 revenue and EPS?
- Relmada Therapeutics, Inc. reported eps of $-0.11 for Q2 2026.
- Did Relmada Therapeutics, Inc. beat estimates in Q2 2026?
- EPS beat the consensus estimate of $-0.20 by $0.09.
- How did Relmada Therapeutics, Inc.'s Q2 2026 results compare year-over-year?
- Compared to the same quarter a year prior, eps grew 63.3% from $-0.30.
- Where can I find Relmada Therapeutics, Inc.'s Q2 2026 SEC filings?
- You can read the 8-K earnings release (0001213900-26-086190) and the 10-Q periodic report (0001213900-26-086151) directly on SEC EDGAR. The filing index links above go to sec.gov.
